AbCellera Biologics (ABCL) Enterprise Value: 2020-2025
Historic Enterprise Value for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $982.5 million.
- AbCellera Biologics' Enterprise Value rose 902.60% to $982.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$876.5 million, marking a year-over-year increase of 58.38%. This contributed to the annual value of $214.8 million for FY2024, which is 75.35% down from last year.
- Latest data reveals that AbCellera Biologics reported Enterprise Value of $982.5 million as of Q3 2025, which was up 120.42% from $445.7 million recorded in Q2 2025.
- AbCellera Biologics' 5-year Enterprise Value high stood at $8.5 billion for Q1 2021, and its period low was $34.2 million during Q1 2025.
- Over the past 3 years, AbCellera Biologics' median Enterprise Value value was $545.2 million (recorded in 2023), while the average stood at $582.9 million.
- Over the last 5 years, AbCellera Biologics' Enterprise Value had its largest YoY gain of 902.60% in 2025, and its largest YoY loss of 94.32% in 2025.
- AbCellera Biologics' Enterprise Value (Quarterly) stood at $3.3 billion in 2021, then slumped by 39.40% to $2.0 billion in 2022, then tumbled by 56.14% to $871.3 million in 2023, then plummeted by 75.35% to $214.8 million in 2024, then soared by 902.60% to $982.5 million in 2025.
- Its last three reported values are $982.5 million in Q3 2025, $445.7 million for Q2 2025, and $34.2 million during Q1 2025.